Expression and purification of recombinant TAT-BoNT/A_(1–448) under denaturing and native conditions

References

• Johnson EA, Bradshaw M. Clostridium Botulinum and Its Neurotoxins: A metabolic and cellular perspective. Toxicon 2001; 39:1703-22; PMID:11595633; http://dx.doi.org/10.1016/S0041-0101(01)00157-X
   PubMed Web of Science ®Google Scholar
• Lacy DB, Tepp W, Cohen AC, Dasgupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type a and implications for toxicity. Nat Struct Biol 1998; 5:898-902; PMID:9783750; http://dx.doi.org/10.1038/2338
   PubMedGoogle Scholar
• Swaminathan S, Eswaramoorthy S. Structural Analysis of the Catalytic and binding sites of clostridium botulinum Neurotoxin B. Nat Struct Biol 2000; 7:693-9; PMID:10932256; http://dx.doi.org/10.1038/78005
   PubMedGoogle Scholar
• Schiavo G, Rossetto O, Santucci A, Dasgupta BR, Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem 1992; 267:23479-83; PMID:1429690
   PubMed Web of Science ®Google Scholar
• Gul N, Smith LA, Ahmed SA. Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form. PLoS One 2010; 5:e12872; PMID:20877571; http://dx.doi.org/10.1371/journal.pone.0012872
   PubMedGoogle Scholar
• Mauskop A. The use of Botulinum Toxin in the treatment of headaches. Curr Pain Headache Rep 2002; 6:320-3; PMID:12095468; http://dx.doi.org/10.1007/s11916-002-0054-1
   PubMedGoogle Scholar
• Mauskop A. Botulinum toxin in headache treatment: The end of the road? Cephalalgia 2007; 27:468; PMID:17448184; http://dx.doi.org/10.1111/j.1468-2982.2007.01290_1.x
   PubMed Web of Science ®Google Scholar
• Verheyden J, Blitzer A. Other noncosmetic uses of Botox. Dis Mon 2002; 48:357-66; PMID:12195265; http://dx.doi.org/10.1053/mda.2001.25136
   PubMed Web of Science ®Google Scholar
• Dhaked RK, Singh MK, Singh P, Gupta P. Botulinum toxin: Bioweapon & magic drug. Indian J Med Res 2010; 132:489-503; PMID:21149997
   PubMed Web of Science ®Google Scholar
• Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002; 27:552-8; PMID:12417130; http://dx.doi.org/10.1016/S0968-0004(02)02177-1
   PubMed Web of Science ®Google Scholar
• Masuyer G, Chaddock JA, Foster KA, Acharya KR. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol 2014; 54:27-51; PMID:24016211; http://dx.doi.org/10.1146/annurev-pharmtox-011613-135935
   PubMed Web of Science ®Google Scholar
• Contractor J A, Wadia F, Patel A, Bamania M, Muppidi V. Papillary thyroid carcinoma in a 4-Year-Old Boy. Indian J Otolaryngol Head Neck Surg 2002; 54:148-9; PMID:23119879
   PubMedGoogle Scholar
• Henriques ST, Melo MN, Castanho MA. Cell-penetrating peptides and antimicrobial peptides: How different are they? Biochem J 2006; 399:1-7; PMID:16956326; http://dx.doi.org/10.1042/BJ20061100
   PubMed Web of Science ®Google Scholar
• Mueller J, Kretzschmar I, Volkmer R, Boisguerin P. Comparison of cellular uptake using 22 Cpps in 4 different cell lines. Bioconjug Chem 2008; 19:2363-74; PMID:19053306; http://dx.doi.org/10.1021/bc800194e
   PubMed Web of Science ®Google Scholar
• Schmidt N, Mishra A, Lai GH, Wong GC. Arginine-rich cell-penetrating peptides. FEBS Lett 2010; 584:1806-13; PMID:19925791; http://dx.doi.org/10.1016/j.febslet.2009.11.046
   PubMed Web of Science ®Google Scholar
• Saffarian P, Peerayeh SN, Amani J, Ebrahimi F, Sedighian H, Halabian R, Fooladi AA. Tat-Bont/a(1-448), a novel fusion protein as a therapeutic agent: analysis of transcutaneous delivery and enzyme activity. Appl Microbiol Biotechnol 2016; 100:2785-95; PMID:26711279; http://dx.doi.org/10.1007/s00253-015-7240-7
   PubMed Web of Science ®Google Scholar
• Amani J, Saffarian P, Najar-Peerayeh S, Imani-Fooladi AA. Designing and analyzing the structure of Tat-Bont/a(1–448) fusion protein: an in silico approach. 2014; 3:13
   Google Scholar
• Kim DW, Kim SY, An JJ, Lee SH, Jang SH, Won MH, Kang TC, Chung KH, Jung HH, Cho SW, et al. Expression, purification and transduction of Pep-1-Botulinum Neurotoxin Type a (Pep-1-Bont/a) into Skin. J Biochem Mol Biol 2006; 39:642-7; PMID:17002886; http://dx.doi.org/10.5483/BMBRep.2006.39.5.642
   PubMedGoogle Scholar
• Jensen MJ, Smith TJ, Ahmed SA, Smith LA. Expression, purification, and efficacy of the type a botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 2003; 41:691-701; PMID:12727273; http://dx.doi.org/10.1016/S0041-0101(03)00042-4
   PubMed Web of Science ®Google Scholar
• Lacy DB, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 1999; 291:1091-104; PMID:10518945; http://dx.doi.org/10.1006/jmbi.1999.2945
   PubMed Web of Science ®Google Scholar
• Farasat A, Ebrahimi F, Mousavy J, Salehi M B, Rostamian M. Characterization of antibody titer and immunogenic feature of light chain of botulinum neurotoxin Type A. 2013; 4:6.
   Google Scholar
• Rawat R, Ashraf Ahmed S, Swaminathan S. High level expression of the light chain of botulinum neurotoxin serotype C1 and an efficient Hplc assay to monitor its proteolytic activity. Protein Expr Purif 2008; 60:165-9; PMID:18482846; http://dx.doi.org/10.1016/j.pep.2008.03.010
   PubMed Web of Science ®Google Scholar
• Chaddock JA, Herbert MH, Ling RJ, Alexander FC, Fooks SJ, Revell DF, Quinn CP, Shone CC, Foster KA. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of clostridium botulinum toxin Type A. Protein Expr Purif 2002; 25:219-28; PMID:12135553; http://dx.doi.org/10.1016/S1046-5928(02)00002-5
   PubMed Web of Science ®Google Scholar